Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib, Multi-center, Study of Talquetamab in Combination With Iberdomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

NCT06348108 is registered in ClinicalTrials.gov with Alfred Chung, MD as lead sponsor.

NCT NCT06348108
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06348108 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib, Multi-center, Study of Talquetamab in Combination With Iberdomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Lead sponsor
Alfred Chung, MD
Phase
Phase 1
Overall status
Recruiting
Start date
July 28, 2025
Completion date
July 31, 2029
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, refractory multiple myeloma, relapsed multiple myeloma